keyword
MENU ▼
Read by QxMD icon Read
search

Hypercholesterolemia

keyword
https://www.readbyqxmd.com/read/29773150/anxiety-depression-and-health-related-quality-of-life-in-heterozygous-familial-hypercholesterolemia-a-systematic-review-and-meta-analysis
#1
Leo E Akioyamen, Jacques Genest, Shubham D Shan, Happy Inibhunu, Anna Chu, Jack V Tu
BACKGROUND: Heterozygous familial hypercholesterolemia (FH) is a common genetic disease predisposing affected individuals to a high risk of cardiovascular disease. Yet, considerable uncertainty exists regarding its impact on psychosocial wellbeing. OBJECTIVES: We performed a systematic review and meta-analysis of the association between FH and symptoms of anxiety and depression, and health-related quality of life (HRQL). METHODS: We searched MEDLINE, EMBASE, Global Health, the Cochrane Library, PsycINFO, and PubMed for peer-reviewed literature published in English between January 1, 1990 and January 1, 2018...
June 2018: Journal of Psychosomatic Research
https://www.readbyqxmd.com/read/29771779/cost-of-integrating-non-communicable-disease-screening-into-home-based-hiv-testing-and-counseling-in-south-africa
#2
Ilya Golovaty, Monisha Sharma, Alastair Van Heerden, Heidi van Rooyen, Jared M Baeten, Connie Celum, Ruanne V Barnabas
INTRODUCTION: Integrated HIV-non-communicable disease (NCD) services have the potential to avert death and disability, but require data on program costs to assess the impact of integrated services on affordability. METHODS: We estimated the incremental costs of NCD screening as part of home-based HIV testing and counseling (HTC) and referral to care in KwaZulu-Natal, South Africa. All adults in the households were offered integrated HIV-NCD screening (for HIV, diabetes, hypertension, hypercholesterolemia, obesity, depression, tobacco and alcohol use), counseling, and linkage to care...
May 10, 2018: Journal of Acquired Immune Deficiency Syndromes: JAIDS
https://www.readbyqxmd.com/read/29770718/a-systematic-literature-review-comparing-methods-for-the-measurement-of-patient-persistence-and-adherence
#3
Carol A Forbes, Sohan Deshpande, Francesc Sorio-Vilela, Lucie Kutikova, Steven Duffy, Ioanna Gouni-Berthold, Emil Hagström
OBJECTIVES: A systematic literature review was conducted comparing different approaches estimating persistence and adherence in chronic diseases with polypharmacy of oral and subcutaneous treatments. METHODS: This work followed published guidance on performing systematic reviews. Twelve electronic databases and grey literature sources were used to identify studies and guidelines for persistence and adherence of oral and subcutaneous therapies in hypercholesterolemia, type 2 diabetes, hypertension, osteoporosis and rheumatoid arthritis...
May 17, 2018: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/29770337/-chlamydia-pneumoniae-infection-exacerbates-atherosclerosis-in-apob100only-ldlr-mouse-strain
#4
Ildikó Lantos, Valéria Endrész, Dezső Péter Virok, Andrea Szabó, Xinjie Lu, Tímea Mosolygó, Katalin Burián
Aims: Hyperlipidaemia model animals have been used to elucidate the role of Chlamydia pneumoniae (Cpn) infection in atherosclerosis. The aims of this study were to investigate the proatherogenic effect of multiple Cpn infections in ApoB100only/LDLR-/- mice which based on lipid profile can be regarded as the most suitable mouse model of human hypercholesterolemia and to compare the lesion development to that in a major atherosclerosis model ApoE-/- mice. Methods and Results: Aorta samples of ApoB100only/LDLR-/- mice infected three times with Cpn were subjected to morphometric analyses...
2018: BioMed Research International
https://www.readbyqxmd.com/read/29770231/cardiovascular-outcomes-of-pcsk9-inhibitors-with-special-emphasis-on-its-effect-beyond-ldl-cholesterol-lowering
#5
REVIEW
Dhrubajyoti Bandyopadhyay, Kumar Ashish, Adrija Hajra, Arshna Qureshi, Raktim K Ghosh
PCSK9 inhibitors, monoclonal antibodies, are novel antihypercholesterolemic drugs. FDA first approved them in July 2015. PCSK9 protein (692-amino acids) was discovered in 2003. It plays a major role in LDL receptor degradation and is a prominent modulator in low-density lipoprotein cholesterol (LDL-C) metabolism. PCSK9 inhibitors are monoclonal antibodies that target PCSK9 protein in liver and inhibiting this protein leads to drastically lowering harmful LDL-C level in the bloodstream. Despite widespread use of the statin, not all the high-risk patients were able to achieve targeted level of LDL-C...
2018: Journal of Lipids
https://www.readbyqxmd.com/read/29769708/maternal-supraphysiological-hypercholesterolemia-associates-with-endothelial-dysfunction-of-the-placental-microvasculature
#6
Bárbara Fuenzalida, Bastián Sobrevia, Claudette Cantin, Lorena Carvajal, Rocío Salsoso, Jaime Gutiérrez, Susana Contreras-Duarte, Luis Sobrevia, Andrea Leiva
Maternal physiological or supraphysiological hypercholesterolemia (MPH, MSPH) occurs during pregnancy. MSPH is associated with foetal endothelial dysfunction and atherosclerosis. However, the potential effects of MSPH on placental microvasculature are unknown. The aim of this study was to determine whether MSPH alters endothelial function in the placental microvasculature both ex vivo in venules and arterioles from the placental villi and in vitro in primary cultures of placental microvascular endothelial cells (hPMEC)...
May 16, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29769597/long-term-risk-for-end-stage-kidney-disease-and-death-in-a-large-population-based-cohort
#7
Emanuel Zitt, Constanze Pscheidt, Hans Concin, Reinhard Kramar, Raphael S Peter, Jan Beyersmann, Karl Lhotta, Gabriele Nagel
Knowledge of metabolic risk factors for end-stage kidney disease (ESKD) in the general population is limited when considering the competing event death in risk analysis. The aim of our prospective observational study was to investigate how blood pressure and metabolic factors might influence the risks for ESKD and death before ESKD in a large Austrian population-based cohort with long-term follow-up. 177,255 participants (53.8% women; mean age 42.5 years) were recruited between 1988 and 2005 and linked to the Austrian Dialysis and Transplant Registry and the National Mortality Registry...
May 16, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29763593/midlife-vascular-risk-factors-and-midlife-cognitive-status-in-relation-to-prevalence-of-mild-cognitive-impairment-and-dementia-in-later-life-the-atherosclerosis-risk-in-communities-study
#8
David S Knopman, Rebecca F Gottesman, A Richey Sharrett, Amanda L Tapia, Sonia DavisThomas, B Gwen Windham, Laura Coker, Andrea L C Schneider, Alvaro Alonso, Josef Coresh, Marilyn S Albert, Thomas H Mosley
INTRODUCTION: The interplay between midlife vascular risk factors and midlife cognitive function with later life mild cognitive impairment (MCI) and dementia (DEM) is not well understood. METHODS: In the Atherosclerosis Risk in Communities Study, cardiovascular risk factors and cognition were assessed in midlife, ages 45-64 years. In 2011-2013, 20-25 years later, all consenting Atherosclerosis Risk in Communities participants underwent a cognitive and neurological evaluation and were given adjudicated diagnoses of cognitively normal, MCI, or DEM...
May 12, 2018: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
https://www.readbyqxmd.com/read/29760789/higher-cardiometabolic-risk-in-idiopathic-versus-autoimmune-type-1-diabetes-a-retrospective-analysis
#9
Valentina Guarnotta, Enrica Vigneri, Giuseppe Pillitteri, Alessandro Ciresi, Giuseppe Pizzolanti, Carla Giordano
Background: Idiopathic type 1 diabetes mellitus (IDM) is characterized by an onset with insulinopenia and ketoacidosis with negative β-cell autoimmunity markers and lack of association with HLA. The aim of the study is to compare the clinical and metabolic parameters, the macro and microvascular complications, the adipose tissue dysfunction and the insulin secretion and sensitivity indexes in patients with IDM and autoimmune type 1 diabetes mellitus (ADM) at clinical onset. Methods: Thirty patients with IDM and 30 with ADM, matched for age and gender, were retrospectively analyzed...
2018: Diabetology & Metabolic Syndrome
https://www.readbyqxmd.com/read/29760721/decreased-count-and-dysfunction-of-circulating-epcs-in-postmenopausal-hypercholesterolemic-females-via-reducing-no-production
#10
Ying Luo, Quan-Neng Yan, Wan-Zhou Wu, Fan-Yan Luo
Endothelial progenitor cells (EPCs) contribute to the endogenous endothelial repair program during hypercholesterolemia. EPC count and migratory and proliferative capacities remain unchanged in the premenopausal female with hypercholesterolemia. However, the changes of count and activity of circulating EPCs in the hypercholesterolemic postmenopausal females are unknown. Here, we find that the migratory and proliferative capacities of circulating EPCs were decreased in patients with hypercholesterolemia versus normocholesterolemia...
2018: Stem Cells International
https://www.readbyqxmd.com/read/29759592/ccdc115-cdg-a-new-rare-and-misleading-inherited-cause-of-liver-disease
#11
Muriel Girard, Aurélia Poujois, Monique Fabre, Florence Lacaille, Dominique Debray, Marlène Rio, François Fenaille, Sophie Cholet, Coralie Ruel, Elizabeth Caussé, Janick Selves, Laure Bridoux-Henno, France Woimant, Thierry Dupré, Sandrine Vuillaumier-Barrot, Nathalie Seta, Laurent Alric, Pascale de Lonlay, Arnaud Bruneel
Congenital disorders of glycosylation (CDG) linked to defects in Golgi apparatus homeostasis constitute an increasing part of these rare inherited diseases. Among them, COG-CDG, ATP6V0A2-CDG, TMEM199-CDG and CCDC115-CDG have been shown to disturb Golgi vesicular trafficking and/or lumen pH acidification. Here, we report 3 new unrelated cases of CCDC115-CDG with emphasis on diagnosis difficulties related to strong phenotypic similarities with mitochondriopathies, Niemann-Pick disease C and Wilson Disease. Indeed, while two individuals clinically presented with early and severe liver fibrosis and cirrhosis associated with neurological symptoms, the other one "only" showed isolated and late severe liver involvement...
May 9, 2018: Molecular Genetics and Metabolism
https://www.readbyqxmd.com/read/29758414/role-of-pcsk9-in-lipid-metabolism-and-atherosclerosis
#12
REVIEW
Xiao-Long Lin, Le-Le Xiao, Zhi-Han Tang, Zhi-Sheng Jiang, Mi-Hua Liu
Elevated plasma low-density lipoprotein cholesterol (LDL-C) is an important risk factor for cardiovascular diseases. Statins are the most widely used therapy for patients with hyperlipidemia. However, a significant residual cardiovascular risk remains in some patients even after maximally tolerated statin therapy. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a new pharmacologically therapeutic target for decreasing LDL-C. PCSK9 reduces LDL intake from circulation by enhancing LDLR degradation and preventing LDLR recirculation to the cell surface...
May 11, 2018: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/29754649/telemedicine-cardiovascular-risk-reduction-in-veterans-the-cities-trial
#13
Hayden B Bosworth, Maren K Olsen, Felicia McCant, Karen M Stechuchak, Susanne Danus, Matthew J Crowley, Karen M Goldstein, Leah L Zullig, Eugene Z Oddone
BACKGROUND: Comprehensive programs addressing tailored patient self-management and pharmacotherapy may reduce barriers to cardiovascular disease (CVD) risk reduction. METHODS: This is a 2-arm (clinical pharmacist specialist-delivered, telehealth intervention and education control) randomized controlled trial including Veterans with poorly controlled hypertension and/or hypercholesterolemia. Primary outcome was Framingham CVD risk score at 6 and 12 months, with systolic blood pressure; diastolic blood pressure; total cholesterol; low-density lipoprotein; high-density lipoprotein; body mass index; and, for those with diabetes, HbA1c as secondary outcomes...
May 2018: American Heart Journal
https://www.readbyqxmd.com/read/29754453/the-dpp-4-inhibitor-anagliptin-ameliorates-hypercholesterolemia-in-hypercholesterolemic-mice-via-inhibition-of-intestinal-cholesterol-transport
#14
Moritaka Goto, Shinji Furuta, Satoko Yamashita, Hiroyuki Hashimoto, Wataru Yano, Noriyuki Inoue, Noriaki Kato, Kohei Kaku
AIMS/INTRODUCTION: Recent data showed that DPP-4 inhibitors exert a lipid-lowering effect in diabetic patients. However, the mechanism of action is not yet clearly understood. We investigated the effect of anagliptin on cholesterol metabolism and transport in the small intestine using non-diabetic hyperlipidemic animals, to clarify the mechanisms underlying the cholesterol-lowering action. MATERIALS AND METHODS: Male ApoE-deficient mice were orally administered anagliptin in the normal chow...
May 13, 2018: Journal of Diabetes Investigation
https://www.readbyqxmd.com/read/29754388/consumption-of-probiotic-lactobacillus-fermentum-mtcc-5898-fermented-milk-attenuates-dyslipidemia-oxidative-stress-and-inflammation-in-male-rats-fed-on-cholesterol-enriched-diet
#15
Radha Yadav, Suhail Hakeem Khan, Sanusi Bello Mada, Sunita Meena, Rajeev Kapila, Suman Kapila
There is a growing and alarming prevalence that increased serum cholesterol is closely related to increased cardiovascular disease risk. Probiotic consumption could be a safe and natural strategy to combat. Therefore, we sought to examine the cholesterol-lowering potential of co-supplementation of probiotic bacteria Lactobacillus fermentum MTCC: 5898-fermented buffalo milk (2.5% fat) in rats fed cholesterol-enriched diet. Male Wistar rats were divided into three groups on the basis of feed, viz. group 1, fed standard diet (SD); group 2, fed cholesterol-enriched diet (CED); and group 3, fed cholesterol-enriched diet along with L...
May 13, 2018: Probiotics and Antimicrobial Proteins
https://www.readbyqxmd.com/read/29753733/coronary-computed-tomographic-angiography-findings-and-their-therapeutic-implications-in-asymptomatic-patients-with-familial-hypercholesterolemia-lessons-from-the-safeheart-study
#16
Leopoldo Pérez de Isla, Rodrigo Alonso, Ovidio Muñiz-Grijalvo, José Luis Díaz-Díaz, Daniel Zambón, José Pablo Miramontes, Francisco Fuentes, José Juan Gómez de Diego, Aurora González-Estrada, Nelva Mata, Adriana Saltijeral, Manuel Barreiro, Marta Tomás, Raimundo de Andrés, Rosa Argüeso, Maria Pilar Serrano Gotarredona, Silvia Navarro Herrero, Rosario J Perea Palazón, Teresa M de Caralt, Luisa Arrojo Suárez de Centi, Svetlana Zhilina, Simona Espejo Pérez, Teresa Padró, Pedro Mata
BACKGROUND: Familial hypercholesterolemia (FH) confers an increased risk of premature atherosclerotic disease. Coronary computed tomographic angiography (CTA) can assess preclinical coronary atherosclerosis. OBJECTIVES: To describe coronary CTA findings in asymptomatic molecularly defined FH individuals, to identify those factors related to its presence and extension, and to assess the impact of these results in patients' care and estimated risk. METHODS: Four hundred and forty individuals with FH, without clinical cardiovascular disease, were consecutively enrolled and underwent a coronary CTA that was used to analyze coronary atherosclerosis based on coronary calcium score (CCS), sum of stenosis severity, and plaque composition sum (PCS)...
April 17, 2018: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/29749101/understanding-patient-adherence-and-concerns-with-statins-and-medication-discussions-with-physicians-action-a-survey-on-the-patient-perspective-of-dialogue-with-healthcare-providers-regarding-statin-therapy
#17
Eliot A Brinton
BACKGROUND: Statin therapy is used first-line for cholesterol lowering and prevention of atherosclerotic cardiovascular disease (CVD), but side effects and the potential for drug-drug interactions may complicate its use. Provider-patient communication is essential for shared decision-making, which, in turn, is recommended by guidelines to reduce or overcome these challenges. Unfortunately, relatively little is known about provider-patient communication surrounding statin use. METHOD: We conducted an online survey of 5,014 patients, U...
May 10, 2018: Clinical Cardiology
https://www.readbyqxmd.com/read/29748315/genetic-regulation-of-pcsk9-proprotein-convertase-subtilisin-kexin-type-9-plasma-levels-and-its-impact-on-atherosclerotic-vascular-disease-phenotypes
#18
Janne Pott, Valentin Schlegel, Andrej Teren, Katrin Horn, Holger Kirsten, Christina Bluecher, Juergen Kratzsch, Markus Loeffler, Joachim Thiery, Ralph Burkhardt, Markus Scholz
BACKGROUND: Inhibition of PCSK9 (proprotein convertase subtilisin/kexin type 9) is a novel strategy to treat hypercholesterolemia and reduce cardiovascular events. However, the potential role of circulating plasma PCSK9 concentrations as a diagnostic and predictive biomarker remains uncertain as of now. Here, we aimed to identify genetic variants associated with plasma PCSK9 and investigate possible causal effects on atherosclerotic vascular disease phenotypes. METHODS: We performed the first genome-wide association study of plasma PCSK9 levels in a cohort of suspected and confirmed coronary artery disease (LIFE-Heart; n=3290)...
May 2018: Circulation. Genomic and precision medicine
https://www.readbyqxmd.com/read/29747383/current-role-of-lipoprotein-apheresis-in-the-treatment-of-high-risk-patients
#19
REVIEW
Ulrich Julius
Lipoprotein apheresis (LA) is a therapeutic approach to save the lives of patients who are at an extremely high risk of developing cardiovascular events (CVE), especially after all other therapeutic options were not tolerated, or appeared not to be effective enough. Homozygous familial hypercholesterolemia represents a clear indication to start LA therapy. Another recognized indication is a severe hypercholesterolemia, which induced CVE, often in association with other risk factors. In the last years, an expressive elevation of lipoprotein(a) (Lp(a)) emerged as an indication for LA...
May 9, 2018: Journal of Cardiovascular Development and Disease
https://www.readbyqxmd.com/read/29747326/-current-status-and-the-consistency-analysis-of-using-two-criteria-for-decision-making-of-aspirin-use-for-the-primary-prevention-of-ischemic-cardiovascular-disease-in-outpatients
#20
H J Zuo, L Q Deng, J W Wang
Objective: To compare the consistency and accuracy of using 2 criteria for decision making of aspirin use for the primary prevention of ischemic cardiovascular disease (ISCVD) and explore the current status and related factors of aspirin use for the primary prevention of ISCVD in Chinese outpatients. Methods: This cross-sectional study enrolled 3 018 outpatients with hypertension, diabetes, or hypercholesterolemia, who visited the General Practice (GP) clinics of Anzhen hospital in Beijing from September to December 2015 were enrolled in...
April 24, 2018: Zhonghua Xin Xue Guan Bing za Zhi
keyword
keyword
11724
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"